An Introduction to Liraglutide

Posted by: admin on: October 31, 2011

In recent years diabetes is prevailing widely and has become matter of concern. Newer and newer drugs are coming to control diabetes. Recent introduction of Liraglutide seems to be promising.

Team@CMHF


Liraglutide, a once-daily human glucagon-like peptide-1 (GLP-1) analog, was approved by the US Food and Drug Administration in 2010 for the treatment of type 2 diabetes mellitus (T2DM). Glucagon-like peptide-1 enhances insulin secretion and inhibits glucagon in a glucose-dependent manner. The efficacy and safety of liraglutide were evaluated with sitagliptin and in another trial where basal insulin was added to liraglutide + metformin.

At liraglutide doses of 1.2 mg or 1.8 mg once daily, significant mean reductions in glycated hemoglobin (HbA1c) (1%–1.6%) and fasting plasma glucose (15–43 mg/dL), as well as sustained weight loss (2–3 kg) and a low rate of hypoglycemia occurred. Liraglutide provide an important expansion of options for the treatment of T2DM.

Reference: http://www.docguide.com/next-generation-glp-1-therapy-introduction-liraglutide?hash=80445d1a&eid=22199&alrhash=2efbb8-880279c42369cc2f8adcb48a6daaf3d2

 

Leave a Reply

Your email address will not be published. Required fields are marked *

*

CMHF Accredited by Maharashtra Medical Council

Subscribe to our Posts

Enter your email address:



  • drchasrani: Difficult to get such a data, authenticated at that. Try Times of India online library
  • rakesh pore: hi, where can i get genuine information about "10 most common drugs sold in india?" i want it for a local project
  • nilesh dutta: sir, Plz give detail about MBA Sports Management Thanks and Regards

Calculate Your Body Mass Index



Check your Body Mass Index »

    Avocado - 160 kcal in 100g
    160kcal
    Avocado - 160 kcal in 100g
    by Noni